LongCPRXJun 2026
Catalyst Pharmaceuticals Inc.
Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash. U.S. antitrust approval had already been received and shareholders approved the…
CPRX
Which hedge funds are long CPRX?
2 published ideas on Catalyst Pharmaceuticals Inc. across 2 funds — 2 long and 0 short.
Catalyst Pharmaceuticals hedge fund investment theses
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Catalyst Pharmaceuticals: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Funds with a position view
Long theses
LongCPRXJun 2026
Catalyst Pharmaceuticals Inc.
Angelini Pharma agreed to acquire Catalyst for $31.50 per share in cash. U.S. antitrust approval had been received and shareholders approved the transaction after quarter-end…